Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632540 · ClinicalTrials.gov registry record
Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis
A clinical trial, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- 824
- Enrollment target
NCT01632540 is a clinical trial that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 824 participants.
The verdict
NCT01632540 has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- 824 participants
- Enrollment target
Study Summary
This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR). Subjects will respond to monthly online surveys regarding rhinitis control, concomitant medical conditions, concomitant (non-AR) medications, current AR therapy, and adverse events.
Interventions
- DRUG Beclomethasone Dipropionate (BDP) Nasal Aerosol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 824 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632540
The ClinicalTrials.gov registry entry for NCT01632540 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 824 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Beclomethasone Dipropionate (BDP) Nasal Aerosol is the first listed.
NCT01632540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632540 about?
NCT01632540 is a clinical study titled "Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis". This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR). Subjects will respond to monthly online surveys regarding rhinitis control, concomitant medical conditions, concomitant (non-AR) medications, curre...
What is the current status of trial NCT01632540?
This trial is currently completed. The enrollment target is 824 participants. The study started on 2012-07. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01632540?
The interventions under investigation include: Beclomethasone Dipropionate (BDP) Nasal Aerosol (DRUG).
Who is sponsoring clinical trial NCT01632540?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.